Avapritinib in Patients with Advanced Systemic Mastocytosis (advsm): Efficacy and Safety Analysis from the Phase 2 PATHFINDER Study with 3-Year Follow-up Andreas Reiter , Jason Gotlib , Deepti H. Radia , Ivan Alvarez-Twose , Michael W. Deininger , Tracy I. George , Jens Panse , Kristen M. Pettit , Alessandro M. Vannucchi , Uwe Platzbecker , Olivier Hermine , Amro Elshoury , Christina Bulai Livideanu , Ruben Mesa , Celalettin Ustun , Massimo Triggiani , Ingunn Dybedal , Joseph Jurcic , Roberta Zanotti , Lambert F. Span , Stephen T. Oh , Abdulraheem Yacoub , Elizabeth O. Hexner , Prithviraj Bose , Stephanie Lee , Wolfgang R. Sperr , Elizabeth A. Griffiths , Matthew Butler , Ilda Bidollari , Hui-Min Lin , Svetlana Rylova , Javier I. Munoz-Gonzalez , Daniel J. DeAngelo CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2024）
Key words
MPN, systemic mastocytosis, tyrosine kinase inhibitor, c-kit
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
